DSpace Repository

In silico design and analysis of recombinant vaccine against Clostridium perfringens Type A and Type E.

Show simple item record

dc.creator NORİZADEH TAZEHKAND, Mostafa
dc.date 2020-06-15T00:00:00Z
dc.date.accessioned 2020-07-27T10:22:38Z
dc.date.available 2020-07-27T10:22:38Z
dc.identifier https://dergipark.org.tr/tr/pub/sdusbed/issue/54917/680719
dc.identifier 10.22312/sdusbed.680719
dc.identifier.uri http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/50980
dc.description Objective: Clostridium perfringens is a spore-forming, anaerobic, gram positive, bacteria that exist in environment, soils, foods, and in intestinal traces of humans or animals. However, vaccines being developed for use in animals have the potential to be developed for use in humans. This study was aimed to design and analysis of multi epitope vaccine against Clostridium perfringens type A and E.Material-Method: The B cell epitopes were predicted by IEDB and MHC II epitopes were predicted by Vaxign web server. Results: Physicochemical study of vaccine showed that the designed vaccine is 58.33 kDa. The half-life of candidate vaccine was found to be greater than 100 hours in mammalian cells, greater than 20 hours in yeast, and greater than 10 hours in Escherichia coli. The instability index of vaccine was 28.41 (<40), the aliphatic index was found to be 47.51, and the vaccine is soluble in water and is considered stable. The grand average of hydropathicity of candidate vaccine is -1.283, consequently, the vaccine is a hydrophilic protein and easily soluble in water. The result obtained from of Toxinpred and Allertop revealed that the protein don’t have tixic and allergenic effect on human and animal cells. Pepcalc and Protparam analysis showed that the vaccine doesn’t have transmembrane helix in its structure, so no expression difficulties are expected in the development of the protein from recombinant dNa technology methods. The result obtained from docking analysis proved that the vaccine has maximum affinity to HLA-DRB1*0101 with the score of -660.73. Conclusion: The result of this study showed that the candidate vaccine can be stimulate HLA-DRB1*0101 and other MCHII alleles.
dc.description Objective: Clostridium perfringens is a spore-forming, anaerobic, gram positive, bacteria that exist in environment, soils, foods, and in intestinal traces of humans or animals. However, vaccines being developed for use in animals have the potential to be developed for use in humans. This study was aimed to design and analysis of multi epitope vaccine against Clostridium perfringens type A and E.Material-Method: The B cell epitopes were predicted by IEDB and MHC II epitopes were predicted by Vaxign web server. Results: Physicochemical study of vaccine showed that the designed vaccine is 58.33 kDa. The half-life of candidate vaccine was found to be greater than 100 hours in mammalian cells, greater than 20 hours in yeast, and greater than 10 hours in Escherichia coli. The instability index of vaccine was 28.41 (<40), the aliphatic index was found to be 47.51, and the vaccine is soluble in water and is considered stable. The grand average of hydropathicity of candidate vaccine is -1.283, consequently, the vaccine is a hydrophilic protein and easily soluble in water. The result obtained from of Toxinpred and Allertop revealed that the protein don’t have tixic and allergenic effect on human and animal cells. Pepcalc and Protparam analysis showed that the vaccine doesn’t have transmembrane helix in its structure, so no expression difficulties are expected in the development of the protein from recombinant dNa technology methods. The result obtained from docking analysis proved that the vaccine has maximum affinity to HLA-DRB1*0101 with the score of -660.73. Conclusion: The result of this study showed that the candidate vaccine can be stimulate HLA-DRB1*0101 and other MCHII alleles.
dc.format application/pdf
dc.language en
dc.publisher Süleyman Demirel University
dc.publisher Süleyman Demirel Üniversitesi
dc.relation https://dergipark.org.tr/tr/download/article-file/1147743
dc.source Volume: 11, Issue: 2 138-143 en-US
dc.source 2146-1937
dc.source 2146-247X
dc.source Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi
dc.subject B cell,Clostridium perfringens,HLA-DRB1*0101,Type E,Type A,Vaccine
dc.subject Vaccine,Clostridium perfringens
dc.title In silico design and analysis of recombinant vaccine against Clostridium perfringens Type A and Type E. en-US
dc.title Design and Analysis of Recombinant Vaccine Against Clostridium Perfringens Type A and Type E tr-TR
dc.type info:eu-repo/semantics/article


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account